⌕
Arcturus Therapeutics Holdings · ARCT · Nasdaq
Tenet 61 · Solid
Compare
$8.31−0.60%At closeTenet 61 · Solid
$8.31−0.05 (−0.60%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Arcturus Therapeutics Holdings (ARCT) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 60% below its peak, net margin −80.2%.
The four lines that matter · FY21–FY25
Revenue ($M)▼46.1%
82.0
FY21→FY25CAGR +60.5%/yr
Net income ($M)▲18.7%
−65.8
one-off year: see footnoteCAGR —
Free cash flow ($M)▼23.4%
−74.5
FY21→FY25CAGR —
Diluted EPS▲20.0%
−2.40
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+4.1%

26.3mn → 27.4mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.

Capex
$230.0K

−64.5% YoY in FY25 · 0.3% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)82.0Revenue0.0COGS82.0Gross profit−112.2R&D−46.1SG&A−76.3Op income10.5Tax & other−65.8Net income

-80¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%FY21FY25

Over this window: gross 100.0% → 100.0%. Net margin -80.2% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
30,514.082,031.0152,310.0166,799.0205,999.012,359.0▼46.1%+60.5%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
30,514.082,031.0152,310.0166,799.0205,999.012,359.0▼46.1%+60.5%
Research & development
80,515.0112,212.0195,156.0192,133.0147,751.0173,760.0▼42.5%−10.4%
Selling, general & admin
44,966.046,079.052,823.052,871.046,071.041,451.0▼12.8%+2.7%
Total operating expenses
125,481.0158,291.0247,979.0245,004.0193,822.0215,211.0▼36.2%−7.4%
Operating incomefeeds ROC rank
−94,967.0−76,260.0−95,669.0−78,205.012,177.0−202,852.0▲20.3%—
Other income, net
7,721.010,477.014,724.050,315.0−1,533.0−822.0——
Pretax income
−87,246.0−65,783.0−80,945.0−27,890.010,644.0−203,674.0▲18.7%—
Income tax
—0.0−4.01,835.01,295.00.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−87,242.0−65,783.0−80,941.0−29,725.09,349.0−203,674.0▲18.7%—
Per share
Diluted EPSbuyback-sensitive
−3.10−2.40−3.00−1.120.35−7.74▲20.0%—
Diluted shares (mn)
28.4427.3927.0026.6327.0926.32▲1.4%+1.0%
Margins
Gross margin82nd pct in Healthcare
100.0%100.0%100.0%100.0%100.0%100.0%▲0.0pp+0.0pp
Operating margin
−311.2%−93.0%−62.8%−46.9%5.9%−1641.3%▼30.2pp+1548.4pp
Net margin24th pct in Healthcare
−285.9%−80.2%−53.1%−17.8%4.5%−1648.0%▼27.1pp+1567.8pp
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was 12% vs a 0% norm for this window, likely a one-time item; see the filing.
FY18 – FY20 · 3 more years
Unlock the full history →
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-03 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Arcturus Therapeutics Holdings' revenue last fiscal year?

Arcturus Therapeutics Holdings reported revenue of $82.0M in fiscal 2025, down 46.1% from fiscal 2024.

What was Arcturus Therapeutics Holdings' net income?

Arcturus Therapeutics Holdings reported net income of −$65.8M in fiscal 2025, a net margin of −80.2%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.